Newsroom | 74536 results
Sorted by: Latest
-
The Science Behind Plan B: How Emergency Contraception Actually Works, According to OB/GYN Lauren Streicher, M.D.
NEW YORK--(BUSINESS WIRE)--THE SCIENCE BEHIND PLAN B: HOW EMERGENCY CONTRACEPTION ACTUALLY WORKS, ACCORDING TO OB/GYN LAUREN STREICHER, M.D....
-
Chemtrade Logistics Income Fund Declares November 2026 Distribution
TORONTO--(BUSINESS WIRE)--Chemtrade Logistics Income Fund Declares November 2026 Distribution...
-
Scientific Research and Virtual Universes Reveal the Secrets of the Lighthouse of Alexandria
PARIS--(BUSINESS WIRE)--More than 2,000 years after it was built, the legendary lighthouse of Alexandria is being brought back to life through scientific research and the use of virtual universes. For the first time, a scientifically complete 3D reconstruction reveals how one of the Seven Wonders of the World was built.Rising some 100 meters above the Mediterranean, this masterpiece of civil engineering dominated the coastline for nearly 16 centuries and withstood 18 earthquakes before its light...
-
Axoft Unveils Meaningful Clinical Momentum of Its Ultra-Soft Fleuron™ Brain Computer Interface Probes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced multiple data milestones from ongoing clinical use of its ultra-soft Fleuron™ Brain Computer Interface (BCI) depth probes at Mass General Brigham (MGB) and The Panama Clinic. Built to leverage the naturally scalable language of the brain, Axoft’s high-density BCIs use the company’s proprietary Fleuron material, which enables high quality neural data capture over longer periods of time due to the material’s supe...
-
Enko and Syngenta Advance Novel Fungicide Chemistry
MYSTIC, Conn.--(BUSINESS WIRE)--Enko Chem, Inc. announced that its novel fungicide chemistry has advanced to a second year of field testing. First-season trials spanning Europe, North America and Asia demonstrated that disease control first observed in the greenhouse translated to real-world field conditions. The milestone marks an important step in Enko's efforts to bring new modes of action to crop protection. Fungal diseases threaten crop yields worldwide, while the development of resistance...
-
PANCAID Consortium Adopts biomodal's duet 6-base mosaic Technology to Advance Early Detection of Pancreatic Cancer
CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced that PANCAID (PANcreatic CAncer Initial Detection via liquid biopsy), a pan-European research consortium uniting 18 partner institutions across eight countries, has adopted biomodal’s duet 6-base mosaic sequencing technology to explore complementary genetic, epigenetic and fragmentomic biomarkers in circulating cell-free DNA (cfDNA) from patients with pancrea...
-
PPG inducts six new members into Collegium association
PITTSBURGH--(BUSINESS WIRE)--PPG (NYSE:PPG) today announced the induction of six new members into its Collegium, an association of longstanding PPG leaders who have made significant technological contributions that support the company’s growth, innovation and ability to serve customers. “This year’s Collegium inductees demonstrate how innovation creates value, from developing new technologies and applications to transforming manufacturing and helping our customers operate more efficiently and s...
-
Circus Brings Autonomous Robotics into Hospital Nutrition; Launched with Schoen Clinic Group
MUNICH--(BUSINESS WIRE)--Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), a Physical AI company developing AI robotics for autonomous meal production, has successfully launched its CA-1 robotic technology in hospital care. Schoen Clinic is the launch customer in the sector, with autonomously produced fresh meals now available to patients, medical teams and visitors around the clock.The launch was realised at Schoen Clinic Munich Harlaching, an internationally recognised orthopaedic spe...
-
GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial
CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is...
-
CitroTech Appoints National Wildfire Leader and American Forests President and CEO Hilary Franz to Board of Directors
GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--CitroTech (NYSE AM: CITR), a specialty chemical company developing environmentally responsible fire-inhibitor solutions, today announced the appointment of Hilary Franz to its Board of Directors. She will serve on the Board’s Audit and Compensation Committees. Ms. Franz is President and CEO of American Forests, the nation’s oldest nonprofit dedicated to forest stewardship and reducing catastrophic wildfires. From 2017 to 2025, she served two terms as W...